慢性鼻窦炎伴鼻息肉生物制剂当代应用指南:NIH研讨会讨论
本文源自2019年美国国立卫生研究院(NIH)赞助的研讨会,由医生和科学家讨论生物制剂治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的未来研究方向。由于知识缺口,会议形成共识并提出当前使用建议:医生应个体化评估患者,并密切监测疗效,因生物制剂成本高且长期影响未知。
要点
- 生物制剂是CRSwNP的新治疗选择,但患者选择与指征尚存疑问。
- 建议个体化评估患者,密切监测病情改善。
- 生物制剂成本高且长期效应未知,需谨慎使用。
核心结论
- 建议医生个体化评估CRSwNP患者,并密切监测生物制剂疗效,因成本高且长期影响未知。
主要发现
- 研讨会讨论了患者选择、指征、临床疗效和成本效果等问题,并指出知识缺口需要共识。
关键数值与推荐
- 建议个体化评估患者并密切监测改善,因生物制剂成本高且长期效应未知。
临床怎么用
- 临床使用生物制剂治疗CRSwNP时,应基于个体化评估,并密切监测治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic medications are emerging as options for treating chronic rhinosinusitis with nasal polyps (CRSwNP). Several questions remain regarding patient selection, indications, clinical efficacy, and cost effectiveness. METHODS: In November 2019, a group of physicians and scientists gathered to consider strategies for future studies regarding biologics. During the discussion, gaps in knowledge highlighted a need for a consensus on the present day use of biologics in polyp patients. RESULTS: The goal of this guideline is to propose recommendations for the current use of biologics in CRSwNP as new evidence continues to emerge and inform practice. CONCLUSION: We suggest that physicians evaluate patients on an individual basis and closely monitor for improvement due to the high cost and unknown long-term effects of biologics.
引用
- Roland LT, Smith TL, Schlosser RJ, et al. Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop. Int Forum Allergy Rhinol. 2020. PMID: 32484603. doi:10.1002/alr.22633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。